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Summary Our previous studies showed that carboxymethyl benzylamide dextran (CMDB7) blocks basic fibroblast growth factor (FGF-2)-
dependent cell proliferation of a human breast epithelial line (HBL100), suggesting its potential role as a potentantiangiogenic substance. The
derived cell line (HH9), which was transformed with the hst/FGF4 gene, has been shown to be highly proliferative in vitro and to induce
angiogenic tumours in nude mice. We show here that CMDB7 inhibits the mitogenic activities of the conditioned media from HBL 100 and
HH9 cells in a dose-dependent manner. When HH9 cells were injected s.c. into nude mice, CMDB7 treatment (300 mg kg-' week-')
suppressed the tumour take and the tumour growth by about 5Oi/o and 80% respectivety. Immunohistochemical analysis showed a highly
significant decrease, by more than threefold, in the endothelial density of viable tumour regions, together with a significant increase in the
necrosis area. This antiangiogenic activity of CMDB7 was further demonstrated by direct inhibition of calf pulmonary artery (CPAE) and
human umbilical vein (HUVEC) endothelial cell proliferation and migration in vitro. In addition, we showed that CMDB7 inhibitsspecifically the
mitogenic effects ofthe growth factors that bind to hepann such as FGF-2, FGF-4, platelet-derived growth factor (PDGF-BB) and transforming
growth factor (TGF-p1), but not those of epidermal growth factor (EGF) and insulin-like growth factor (IGF-1). These results demonstrate that
CMDB7 inhibits FGF-2/FGF-4-dependent tumour growth and angiogenesis, most likety by disrupting the autocrine and paracrine effects of
growth factors released from the tumour cells.
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Fibroblast arowth factors (FGFs) are a nine-member family of
proteins that exhibit potent mitogenic activitv towards cells of
mesenchvmal. neuronal and epithelial origin (Basilico and
Moscatelli. 1992: Tanaka et al. 1992: Mivamoto et al. 1993). FGFs
require heparin as a co-factor for their interaction with the recep-
tors. Although some FGFs do not possess a signal sequence. all of
them appear to be secreted and accumulated in the extracellular
matrix (Klagsbrun. 1989). In the human mammary gland. FGF-2 is
localized in the area of myoepithelial and epithelial cells (Gomm
et al. 1991 ). Clinical studies indicate that these growth factors may
be involved in breast cancer development. For example. FGF-1.
FGF-2. FGF-receptor I (FGF-RI). FGF-R2 and FGF-R3 gene
expression has been detected in breast cancer (Penault-Lorca et al.
1995). and FGF3 and FGF4 genes are up-regulated in 20%c of
breast cancer (Theillet et al. 1989). In some breast cancer patients
FGF-2 is abnormallv elevated in the serum or urine (Takei et al.
1993: Nguyen et al. 1994).
A number of studies have shown that FGFs are involved in
tumorigenesis and metastasis in vivo (Dickson et al. 1984:
Murakami et al. 1990: Wellstein et al. 1991 ). For example. MCF-7
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cells transfected by FGF4 become tumorigenic and metastatic
when xenografted in nude mice. even in the absence ofoestrogens
(Mcleskev et al. 1993). FGF-2 exerts angiogenic actixity in viVo
(Czubayko et al. 1994) and induces proliferation. protease produc-
tion and migration of endothelial cells in vitro (Sato and Rifkin.
1988: Tsuboi et al. 1990: Gualandris et al. 1994). FGF-2-over-
expressing endothelial cells acquire an angiogenic phenotype and
recruit quiescent endothelium originating in angioproliferatixve
lesions in vivo (Gualandris et al. 1996).
In previous studies. we have shown that the FGF-2 autocrine
path,vAay can be involved in tumour progression. The HBLIOO
cells. not tumorigenic in nude mice. produce and secrete FGF-2.
wx-hich stimulates their growth in an autocrine manner (Souttou et
al. 1994). The cell lines obtained by transfection of human breast
epithelial HBL100 cells w-ith the activated FGF4 oncogene
develop colonies in soft agar and produce highly vascularized
tumours as a result of the production and secretion of both FGF-2
and FGF4. which can act as autocrine and paracrine factors. But
the presence ofFGF-1. insulin-like growth factors (IGF-1. IGF-2).
transforming growth factors (TGF-cs. TGFS-1) and platelet-
derived growth factor (PDGF-BB) is not detected in conditioned
medium and in cell extracts of HH9 cells (Souttou et al. 1996).
This cell line may provide an appropriate experimental model for
studying antitumoral and anti-anciogenesis molecules that act on
the autocrine and paracrine regulations oftumour development.
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In prexvious papers. we hax-e show-n that some dextran derivatix es
displayed an in -itro growth inhibitorx activitv on breast pretumour
and tumour cells dependinc on their composition ()Mor&re et al.
1992: Bagheri-Yarmand et al. 1994: Liu et al. 1997). For some of
them. e.g. carbox-meth\l benzylamide dextran (CMIDB). a positiVe
correlation w-as found betw-een the inhibition of cell proliferation
and the oxverall content of benzvlamide. Growxth inhibition w-as
associated w-ith a decrease in the proportion ofS-phase cells and an
accumulation of cells in G phase )Bagherii-Yarmand et al. 1994).
Recently. >-e show-ed that one member ofthese dextran derivatixves.
CMDB7. could exert its antiproliferative action on HBL100 cells
by interfering w-ith the FGF-2 autocrine growth of these cells
(BaTheri-Yarmand et al. 1997). Experimental data that emphasize
the orowxth inhibitors potential of this cytostatic non-toxic
compound led us to examine the activity of CNIDB7 on the breast
cancer experimental model of HH9 tumour in nude mice. In this
paper. using this experimental model. >-e investigated the effect of
CMDB7 on: (a) the in vitro growth ofHH9 cells: (b) the mito2enic
actixities of conditioned medium from HBL100 and HH9 cells on
fibroblasts and endothelial cells: (c) the tumour take and tumour
arowth of HH9 cells in nude mice and the neoxascularization of
these tumours: (d) the in vitro migration and proliferation of
endothelial cells and )e) the mitogenic actixities of purified angio-
genic growth factors on fibroblasts.
MATERIALS AND METHODS
Dextran derivative preparation
W'ater-soluble dextran derivatixve (CMDB7) >-as prepared from
dextran T40 as prexiously described (Chaubet et al. 1995). In
brief. CMDB7 >-as prepared by a statistical substitution ofdextran
in twxo steps: carboxymethylation. follow-ed by coupling of benzy-
lamide. This derixatixve >-as then purified by ultrafiltration and
lyophilized. The chemical composition >-as determined bx acidi-
metric titration and elementan- analy sis of nitrogren (dextran. 0%c:
carboxvmethvl. 70%;: benzylamide. 30%c: mass apparent molec-
ular weight = 80 000gmolFI)
Cell lines
The breast epithelial cell line HBL100 obtained from Dr R
Cassingena (Villejuif. France). wxas established from the milk ofan
apparently healthys woman harbourin2 SV40 genetic information
)Polanowxski et al. 1976). The ras transformed HBL100 cells
(HBL100 ras) wxere obtained from Dr G Goubin (Institut Curie.
France) (Lebeau et al. 1991). The HH9 cell line used in this studx
is a clone of HBL100 cells transformed wxith the FGF-4 oncogene
(Souttou et al. 1996). All epithelial cell lines and Balb/c 3T3
fibroblasts )-ATCC) were grown in Dulbecco's modified Ea2le's
medium (DIENM) Gibco. Life Technologies. France) supple-
mented wxith 2 m2\ L-glutamine. 50 IU ml-l penicillin and
50 .ga ml- streptomycin. and 10% fetal calf serum FCS (Gibco .
at 37-C in a humidified atmosphere containinc 5%; CO-.
Calf pulmonarn artery endothelial CPAE cells ATCC xxere
growxn in MENI supplemented xxith 20% FCS. 2 mI L-glutamine.
50 IU ml- penicillin and 50pig ml-i streptomycin and used
between passages 12 and 20. HUVEC cells were isolated from
freshly delivered umbilical cords obtained from natural or
caesarean births. These cells were groxxn in M1199 supplemented
wxith 20%:- FCS. 2 mNI L-glutamine. 50 IU ml-' penicillin and
50 gn ml-l streptomycin and used betmeen passages 1 and 2.
Growth assays
Epithelial cells in their exponential aroxwth phase wxere seeded at a
density of 1.5 x I0W cells per wxell in 24-wxell tissue culture plates
(Polv-labo. Strasbourg. France) for 24 h to allowx cell attachment in
medium -with 10c FCS. Thev wxere then w-ashed with DMEM and
incubated in the medium Aith 1 Cc FCS and Xarious concentrations
ofCMDB7 (dax zero). At different davs. cells wxere harnested w-ith
0.025% of tr-psin-EDTA (Gibco) and the cell number of each
\vell >-as determined in triplicate using a Coulter counter
(Coultronics. Margencv. France).
Preparation of conditioned medium
Epithelial cells in 150-mm-diameter Petri dishes Polxlabo) w-ere
arow-n to 80&e confluence in DMEM supplemented with 10c FCS.
w-ashed tu-ice wxith DMEM and incubated in 1Oml per dish of
DMIEM containin2 0.1%c bovine serum albumin (BSA) (Sigma
Chemical Co.. France) for 24h at >7-C. The medium %vas then
han-ested. cleared bv centrifugation and stored at-80-C before use.
Measurement of [H]thymidine incorporation in DNA
Balb/c 3T3 fibroblasts (10 cells) w-ere seeded in DMEM supple-
mented wxith lUc- FCS into 24-wxell tissue culture plates. growxn
until confluence. \vashed tw-ice \vith DMEM and incubated for
24 h in serum-free DMEM containing 0.1c BSA. This treatment
rendered the cells quiescent. The medium was then replaced with
conditioned medium (0.75 ml per wxell) and 0.25 ml of DMEM
w-ith or wxithout CMDB7. Cells wxere incubated for an additional
20 h and then for 4 h w-ith DMEM containing 1 uiCi ml' [ H]-
thvmidine (Amersham. Bucks. UK). After being \vashed \vith ice-
cold PBS. the cells were fixed wxith ice-cold 10%e tfichloracetic
acid. and solubilized bv using 0.3 x\ NaOH. The radioactivitv
incorporated >-as counted using a Beckman scintillation counter.
In expenrments w-ith purified growth factors. subconfluent cells
w-ere serum starned for 24 h and then incubated w-ith recombinant
human FGF-2 (Genzvme Diagnostics. Cambrid2e. MA. USA).
recombinant human FGF-4 (RR&D Svstems. Abingdon. UK). ultra-
pure human TGF-51. recombinant human PDGF-BB. recombinant
human EGF. recombinant human IGF-l (TEBU. France) for 20 h.
Cells vvere then labelled for 4 h wxith 1 uCi ml-' [ H]thymidine.
Trichloroacetic acid-precipitable radioactivity >-as then measured
and expressed as c.p.m. incorporated per wxell.
Endothelial cell proliferation assay
CPAE and HUV'EC cells \vere cultured at 4000 cells per w-ell
tissue culture plated in 96 w-ells in complete medium containin2
20'%c FCS. After 24 h. medium >-as remoxed and fresh medium
w-ith 5% FCS and various concentrations of CMDB7 w-ere added
to the cells. Tw-entv-four hours later. ['H]thymidine (.Amersham.
France) >-as added at 1 jCi per \vell. ['H]Thvmidine incorporated
follow-ing 18 h of culture >-as absorbed to a paper filter by a
Skatron harvester (Skatron. Lier. Nor-wav) and the radioactivity
w-as determined in a liquid scintillation counter. Quadruplicate
expenments w-ere repeated at least three times.
Migration assay of endothelial cells
A w-ound >-as created w-ith a scraper in confluent endothelial
monolaver in 35-mm tissue culture dishes (Falcon labwarei so as
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to destroy half of the monolayer. Culture medium and detached
cells were removed. the monolaver washed with culture medium
and fresh complete medium added with or without tested aaents.
Transparent graph paper was then stuck to the bottom ofthe tissue
culture dishes so that the shifting distance ofthe edge ofmigration
could be directly measured. The results of the migration distance
were expressed as a percentage ofthe migration rate ofthe control
cells. The experiments were repeated at least three times.
Xenografts in nude mice
Swiss nulnu male athvrmic mice. 3 weeks old. were obtained from
Charles River. France. Animals were kept in a temperature-
controlled room on a 12:12 light-dark schedule with food and
water ad libitum. HH9 cells were cultivated in DMEM supple-
mented with 10% FCS in T150 plates and harvested at 80%7
confluence. Cells (10-) were inoculated s.c. into the right axillary
region of the flank of nude mice. One week after the tumour cell
inoculation. CMDB7 was injected s.c. close to tumours at a dose of
150 m, kg-' in 0.1 ml ofphosphate-buffered saline (PBS). twice a
week, for 9 weeks. The control group receised s.c. a 0.1 ml injec-
tion of PBS. Tumours were measured along two major axes with
calipers. Tumour Xolume wAas caculated as follows: V= 0.5 x R, R.
where R is the shortest diameter and R, is the longest diameter.
Animals (24 mice) were arbitrarily placed in control (n = 12) and
CMDB7 (n = 12) groups.
Tissue storage and immunohistochemical analysis
Tumour specimens were fixed with a solution of formalin (4%7c)
immediately after surgical resection. The fixed samples were
processed to paraffin in the usual way. and 5-gm sections were
examined in haematoxylin and eosin preparations. Immuno-
histochemical staining using a Universal Kit of LSAB2 (K675-
DAB: Dako. France) was also performed using monoclonal mouse
antibodies against Ki-67 (MIB-l: Immunotech). The number of
positive cells for Ki-67 monoclonal antibody was estimated in
six high-power fields containing 60-80 cells per field (x 400).
Endothelial cells were specifically stained with Griffonia
(Banderaea) simplicifolia lectin (GSL-l). The GSL-l lectin binds
specifically to a-galactosyl residues and marks the vascular
endothelium in mice (Alroy et al. 1987). Sections (5 gm) were
deparaffinized and rehydrated. The endogenous peroxidase was
inactivated with 3% H,O, and washed in Tris-buffered saline
(TBS). pH 7.6. followed by preincubation in FCS for 30 min at
room temperature. The sections were then incubated for 45 min
with biotinylated GSL-1 (Vector Laboratories. Burlingame. CA.
USA) at a concentration of0.01 mcg ml-'. washed with TBS treated
for 30 mmn with an avidin-biotin-peroxidase complex (Vector labo-
ratories) and washed again with TBS. The peroxidase was activated
by incubation for 10 mmn in 0.I M acetate buffer (pH 5.2) containinr
3% H,O, and 3% 3-amino-9-ethvlcarbazole. Finally. the slides
were washed in distilled water and tap water. counterstained with
haematoxylin. dehydrated and coverslipped with permount. The
analysis was performed on regions containing exclusively viable
tumour cells depicted by the haematoxylin stain. In each GSL-1-
stained section of control and of CMDB7-treated tumours. five
areas in exclusively viable regions were selected randomly. Image
analysis of the sections stained for endothelial cells with GSL-1
was performed on a Macintosh (Power Macintosh 8500/120)
computer using the public domain NIH image program (developed
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Figure 1 Inhibition of HH9 cell proliferation by CMDB7. HH9 cells were
plated at a density of 1.5 x 10' cells per well in 24-well plates in DMEM
containing 10%/o FCS. On the folowing day (day 0). the medium was changed
to DMEM with 1% FCS (U) containing 1 giM( ). 5 um (_), 10 gm(-), 25 gm
( ) and 50 gm (A) of CMDB7. At the indicated days, cells were trypsinized
and counted by using a Coufter counter. Values provided from one of the
three independant experiments performed in triplicate (mean + s.d.)
at the US National Institutes ofHealth and available on the Internet
at http://rsb.info.nih.gov/nih-image/). The area of stained endothe-
lial cells was determnined with an experimental errorofless than 5%
by measuring the area above a threshold intensity of stain in each
slice. The ratio of stained area to viewed area yielded an average
endothelial density. The densities were then axeraged in control
tumours and in tumours treated with CMDB7.
Statistical analysis
In the figures. the data are presented as the mean x-alues for a
95% confidence interval. Multiple statistical comparisons were
performed using ANOVA and Mann-Whitney in a multivariate
linear model.
RESULTS
Inhibition of the HH9 cell growth by CMDB7
Increasing concentrations ofCMDB7 ranging from 1 j-ix to 50 JIM
added to HH9 cells resulted in a dose-dependent inhibition of cell
number (Figure 1). We observed a cytostatic effect of CMDB7
with an IC; of about 25 jix after 8 days of treatment (Figure 1).
When CMDB7 was removed from the culture medium after a
4-day treatment cell growth resumed at a rate similar to that
observed in untreated cells (data not shown). HH9 cells cultured
with CMDB7 appeared otherwise healthy: they remained attached
to the plastic tissue culture flask and did not undergo any notice-
able morphological changes. In order to confirm the specific
effects of CMDB7 on FGF-2 and FGF-4. we tested the effect of
CMDB7 on ras transformed HBLlOO-cells. As mutated ras func-
tions downstream of FGF receptor stimulation. CMDB7 did not
affect the growth ofthese cells (data not shown).
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Inhibitory effect of CMDB7 on the paracrine activity of
conditioned medium from HBL100 and HH9 cells on
fibroblasts and endothelial cells
We previously shomved that HH9 cells secrete large amounts of
FGF-2 and FGF4 in the conditioned medium (CM: Souttou et al.
1996). Conditioned media derived from parental HBL100 (CM-
HBL100) and HH9 (CM-HH9) cells w-ere tested for their abilitv to
stimulate [LH]thymidine incorporation into the DNA ofBalb/c3T3
cells in the presence or absence of CMDB7. CM obtained from
HBLIOO and HH9 cells stimulated 2.4- and 3.4-fold respectivelx
the [ H]thx midine DNA uptake in fibroblasts. These stimulations
%sere dose-dependently inhibited by CMDB7: 99%7e inhibition was
found in a concentration of5 gi.M for CM-HBL100 and 63%7 inhibi-
tion at 50 JIm for CM-HH9 (Figure 2A). CMDB7 alone did not
affect the proliferation of fibroblasts in serum-free medium. We
determined that media conditioned bv HBL100 and HH9 cells
stimulated the grow-th of endothelial cells (CPAE) about 15- and
22-fold aboxe control respectively. On CPAE cells. CMDB7 (50
JIM) inhibited the paracrine effect of growth factor(s) secreted by
HBLI00 and HH9 cells bv about 70% and 57% respectivelN
(Figure 2B).
Effect of CMDB7 on HH9 cells xenografted in nude
mice
To study the CMDB7 effect on the tumour appearance. one week
after s.c. inoculation of 10- exponentiallx growing HH9 cells in the
right flank of mice. we injected at the same site. tsice per week.
4 mg of CMDB7 per mouse (150 mg kg-'). Palpable tumours
appeared in 60%7. 70%c and 90%/ of control mice 3. 4 and 8 weeks
after cell injections respectivelv. In mice treated w-ith CMDB7.
palpable tumours appeared in 15%. 40%7 and 50%7 ofmice 5. 6 and
10 weeks after cell injection respectivelv (Figure 3A). CMDB7
decreased the tumour size by 80%7 after 9 weeks oftreatment in the
case of treated mice that developed a tumour (P < 0.00001)
(Figure 3B). Bx measuring proliferating tumour cells w-ith anti-
bodx against nuclear Ki-67 antigen. we showed that all the prolif-
erating activities were similar. both in untreated and treated
tumours (Table 1). Immunostaininc with anti-FGF-2 of HH9
tumours showed that FGF-2 is present in these cells (data not
shown). Necrotic areas in treated tumours (53.4±4.1) were
increased compared w-ith untreated tumours (34.2 ± 5.2)
(P < 0.001) (Table 1). To determine whether the CMDB7-
enhanced necrosis was directly associated w-ith a quantitative
reduction in tumour vascularity. we measured the densitv of the
endothelial cells that composed the microcapillaries in the regions
of viable tumour cells close to the tumour periphers. A specific
biotinvlated lectin interacting with endothelial cells (GSL-1)
enabled us to stain these cells selectively (Figure 4). The densitv of
the endothelial cells (percentage of area occupied by endothelials
cells) was determined by image analysis of the stained area. The
mean percentage of endothelial cell area of control tumours was
7.5 ± 1.5 and ofCMDB7-treated tumours Awas 2.39 ± 0.6 (Table 1).
The reduced endothelial cell densits as a result of CMDB7 treat-
ment was highly significant (P < 0.0001).
CMDB7 inhibits the in vitro endothelial cell proliferation
To test the possibility that CMDB7 exerts its antiangiogenic
actixitv by, impairinc endothelial cell proliferation. the effect of
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Figure 2 Effect of conditioned medium (CM) from HBL100 or HH9 cells on
the DNA synthesis of Ba1b/c3T3 fibroblasts and endotheial cells in the
absence or presence of CMDB7. Subconfluent cultures of Balb/c 3T3
fibroblasts (A) or endotheial cells (CPAE) (B) were growth arrested by serum
starvation for 24 h and then incubated for 20 h in the presence of HBL1 00- or
HH9-conditioked medium in the presence or absence of vanous
concentratons of CMDB7. [HJThymidine incorporation was performed for
4 h. and trichoroacetic acidprecipitable radioacvty was counted. Values
provided from one of the three independent experiments perforrned in
triplicate (mean ± s.d.)
CMDB7 on the CPAE and HWIVEC cell grox-th >-as determined in
Xitro. CMDB7 inhibited these tw o endothelial cell proliferations in
a dose-dependent manner. The calculated IC5, of CMDB7 inhibi-
tion on CPAE and HUVEC cell proliferation was 8 g. and 4 JNi
respectively (Figure SA).
CMDB7 inhibits the in vitro endothelial cell migration
Endothelial cell migration is one of the critical features of neovas-
cularization and wound repair. Therefore. we examined the effect
ofCMDB7 on the in sitro movement of CPAE and HUVEC cells
from an in vitro wound edge. The wound wvas made by removing a
patch of cells from a confluent monolayer with a razor blade.
Endothelial cell migration was determined by the distance
travelled by the cells through the wound edge. The addition of
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Table 1 Changes in percentage of necross and in percentage of
endotheial cell density in control and CMDB7-treated tumours but not in
proliferation indexa
Control tumours CMDB7 tumours
(n=11) (n=6)
Index Ki-67 80+ 2t 78 1
Necrosis (%) 34.2 5.2 53.4 4.1c
(P< 0.001)
Area of endothelial cells (%0) 7.5 1.5 2.39 ± 0.6c
(P < 0.0001)
aMean ± s.d. "The number of positive cells for Ki-67 monockonal antibody
was estimated in six high-power felds containing 60-80 cells per field at
x 400 magnification. Results were described as percentage of cells stained.
cA statstcalty significant change relative to control.
A
B
a
Time (weeks)
Figure 3 Effect of CMDB7 on tumour take and tumour growth in nude mice.
HH9 cells (107) were inoculated s.c. into the right axillary region of the flank
of male nude mice, day 0 (n = 24). Treatrent was started 1 week after
subcutaneous inoculaton of tumour cells and stopped after 9 weeks. CMDB7
was administered s.c. twice a week at 150 mg kg-' ( ) (n = 12). Control mice
were injected with PBS (0) (n = 12). A Values represent percentage of
tumour/number of mice. B Tumour volumes (mm3) are the mean + s.e.m. of
mice beanng a tumour
CMDB7 into the medium without serum inhibited the migration of
the cells into the denuded area (Figure 5B). The CMDB7 inhibi-
tion ofcell movement occurred in a dose-dependent manner. Thus.
49% and 31% inhibitions of CPAE and HUVEC cell movement
were obtained respectively at a CMDB7 concentration of 20 gM
after 24 h (Figure SB).
Figure 4 Microscopic view of histoogical sections of endothelial cells
stained with GSL-1. A Control tumours. B Treated tumours by CMDB7. The
details of the staining procedure are given in Materials and meftods
Corngina magnification x 400)
Inhibitory effect of CMDB7 on fibroblast stimulation by
FGF-2, FGF-4, PDGF-BB and TGF-1 but not EGF and
IGF-1
We studied the mitogenic potency of FGF-2. FGF4. PDGF-BB.
TGF-4. EGF and IGF- 1 in the presence or absence of CMDB7 on
Balb/c3T3 fibroblasts. Figure 6 shows that the addition of
2 ng ml-' FGF-2 or FGF4 enhanced the cell growth about nine-
and sixfold respectively. Under these experimental conditions.
CMDB7 (50 gM) inhibited the FGF-2 cell growth stimulation by
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Figure 6 Effect of various growth factors on the DNA synthesis of Balb/c
3T3 in the presence or absence of CMDB7. Subconfluent cuftures of Balb/c
5 10 3T3 fibroblasts were growth arrested by serum starvation for 24 h and then
incubated for 20 h in the presence of recombinant FGF-2, FGF-4. TGF-P,
EGF, IGF-1 (2 ng mFl) and PDGF-BB (10 ng m-') in the presence or
absence of CMDB7 (50gM). [3H]Thymridine incorporaton was performed for
4 h, and tichloroacetic aciprecipitable radioactvity was counted. Values
provided from one of the three independent experiments performed in
triplicate (mean + s.d.)
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Figure 5 Effect of CMDB7 on prohiferation (A) and migratio
and HUVEC. A After cufture of CPAE and HUVEC in the me
5% FCS for 24 h and futher cutture in the media containing %
concentrations of CMDB7 for 24 h, [3Hthpymidine was added
B Confluent endothelial cells were wounded with a razor bla
were incubated for 24 h with vark)us concentrations of CMDI
the migration distance was expressed as a percentage of tti
of the control cells. The experiments were repeated at least
55% and the FGF4 cell growth stimulation by 3
(Figure 6). In Balb/c3T3 fibroblasts. [7H]thymidine
ration was stimulated to about 5.5-fold when cells M
PDGF-BB (10 ng ml-') for 24 h. CMDB7 (10w
stimulation of fibroblast DNA synthesis by PD(
2.9-fold (P < 0.0001) (Figure 6). Incubation of fi
TGF-01 (2 ng ml-') increased the [3H]thymidine
into fibroblast DNA by about 7.6-fold. CMDB7 (l(
completely abolished the TGF- 1-induced D
(P < 0.0002). CMDB7 alone induced no changes
Balb/c3T3 DNA synthesis compared with the control (Figure 6).
Under the same conditions. EGF and IGF-1 enhanced the thymi-
dine uptake by about three- and twofold respectively. So CMDB7
did not effect EGF and IGF-1 growth stimulation (Figure 6).
DISCUSSION
Previous studies have shown that CMDB7 inhibits HBL100 cell
growth by interfering with the FGF-2 autocrine loop in these cells
(Bagheri-Yarmfand et al. 1997). In this paper. we have shown that
the in vitro proliferation of HH9 cells obtained by transformation
ofHBL100 cells with the hstIFGF4 gene are also inhibited in the
presence ofCMDB7. The CMDB7 treatment ofHH9 tumour cells
delayed the appearance oftumours and reduced tumour incidence.
10 20 Only 50% of treated mice developed a tumour after 10 weeks vs
90% in control mice. In addition. treated tumour volume was only
20% of that in the control group at the end of the treatment. The
in (B) of CPAE number ofproliferating Ki-67-positive tumour cells is identical in
dia containing control and treated tumours. Furthermore. in the CMDB7-treated
for 18 h tumours a reduction of68% in the number ofcapillary vessels has
kde. The cells occurred in viable tumour regions. indicating that this treatment
B7. Evaluation of was attenuating the rate of neovascularization but did not
threetimes completely block the initial activation of angiogenesis. nor the
capability of every capillary to grow. In addition. CMDB7-treated
tumours have more plunifocal necrosis. This reduction in endothe-
lial cell density andconcomitant increase in necrosis lends support
30% P < 0.01) to our hypothesis that CMDB7. by inhibiting angiogenesis and
DNA incorpo- endothelium growth. impairs delivery of nutrients and oxygen.
vere exposed to thereby leading to cell death. These results are in agreement with a
4) reduced the number of studies that demonstrated that angiogenesis plays an
JF-BB to only essential role in tumourgrowth (Folkman. 1990: Kim et al. 1993:
ibroblasts with Vartanian and Weidner. 1994). Inhibition of angiogenesis by
incorporation means of FGF-2 immunoneutralizing monoclonal antibody has
D liM). for 24 h. been reported to be associated with anti-tumour effect in vivo
)NA synthesis (Hon et al. 1991). suggesting that novel therapeutic approaches to
in the level of cancer therapy might involve the use ofantiangiogenic drugs.
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In order to explain this CMDB7 antiangiogenic effect, we have
tested the CMDB7 effect on endothelial cell proliferation, a key
step in the angiogenesis process (Folkman and Klagsbrun, 1987).
CPAE and HUVEC cell proliferation was inhibited by CMDB7. It
is unknown whether this inhibition was due to FGF-2-independent
mechanisms or the inhibition ofan autocrine FGF-2 production by
endothelial cells (Schweigerer et al, 1987). Moreover, this inhibi-
tion of endothelial cell proliferation could be due to interference
with the binding ofangiogenic factors such as FGF-2 or FGF-4 to
endothelial cells (Vaisman et al. 1990). In accord with this hypoth-
esis. we have shown that CMDB7 binds to FGF-2 and prevents the
binding ofradiolabelled FGF-2 to its high- and low-affinity recep-
tors on HBL100 cells (Bagheri-Yarnand et al, 1997). Migration of
endothelial cells. which is also a key step in the angiogenesis
process. mediated by FGF-2 (Sato and Rifkin. 1988). appears less
sensitive to CMDB7 than does endothelial cell proliferation. Thus,
CMDB7 can block neovascularization by directly inhibiting the
angiogenic activity ofendothelial cells.
Furthermore, the reduction in endothelium density caused by
CMDB7 could result from its anti-growth factor activity, blocking
paracrine stimulations of FGF-2 and FGF-4 on both fibroblasts
and endothelial cells. Growth factors secreted by HBL100 and
HH9 cells stimulated the incorporation of[3H]thymidine by quies-
cent cultures of Balb/c3T3 fibroblasts. As FGF-1. IGF-1. IGF-2.
TGF-ct, TGF-.j1 and PDGF-BB are not detected in the conditioned
media ofHH9 cells. stimulation ofthe fibroblasts' DNA synthesis
by HH9-conditioned medium is essentially due to FGF-2 and
FGF-4. The CMDB7 treatment inhibited dose dependently CM-
induced mitogenicity in Balb/c3T3 fibroblasts. However. CMDB7
at 5 gM completely blocks the mitogenic effect of factors secreted
by HBL100 cells but inhibits partially (63%). at 50giM, the stimu-
lation induced by CM from HH9 cells. A possible explanation is
an insufficient dose ofCMDB7 forneutralizing the higherquantity
of growth factors secreted in CM from HH9 cells compared with
HBL100 cells (Souttou et al, 1996). The mitogenic effects ofpuri-
fied FGF-2, FGF-4. PDGF-BB and TGF-i1 on Balb/c3T3 fibro-
blast DNA synthesis is inhibited by CMDB7. In contrast, CMDB7
did not affect DNA stimulation by EGF and IGF-1.
CM from HBLIOO and HH9 cells stimulated the growth of
endothelial cells, 15- and 22-fold above the control respectively
vs 2.4- and 3.4-fold stimulation on fibroblasts, suggesting that
endothelial cells are more sensitive to FGF-2 and FGF-4 factors
than fibroblasts. As CMDB7 partially inhibits the paracrine
stimulation ofconditioned media from HBL100 and HH9 cells on
endothelial cells, it is likely that there is not a sufficient amount of
CMDB7 to complex completely these angiogenic factors.
It was proposed that tumours might release factors able to
stimulate expression, production and release ofFGF-2 in and from
capillary endothelial cells and so stimulate angiogenesis. Once the
tumours are invaded by the capillaries, local release of FGF-2
could further enhance the growth of FGF-sensitive tumours
(Schweigerer et al. 1987). We believe that the in vivo effect of
CMDB7 is most probably due to its interaction with the FGF-2 and
FGF-4 released from tumours. Mammary stromal fibroblasts may
also produce factors that exert influence on the growth and
malignant progression of breast tumours via paracrine effects on
tumour-associated endothelium (Hatky et al, 1994).
In conclusion, the present report shows that CMDB7 is an
effective inhibitor of FGF-2 and FGF-4 mitogenic activity for
fibroblasts and endothelial cells in vitro and a potent inhibitor
for angiogenesis-dependent tumour growth in vivo. Thus, this
compound should be an interesting candidate for developing new
anti-cancer drugs, not only because of its potent inhibitory effect
on tumour induced angiogenesis, but also because ofits extremely
low toxicity in vitro as well as in vivo.
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